INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 7, July 2026 | ISSN: 2456-4184 | IJNRD.ORG

PHARMACIST INTERVENTIONS IN CHEMOTHERAPY CARE: A CLINICAL AND OPERATIVE PERSPECTIVE

Vishnumaya A M[1]/ Grace N Raju[2]/ Shaiju S Dharan[3]

[1]PharmD Intern, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram

[2]AssistantProfessor, Department of Pharmacy Practice Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram

[3]Principal/HOD, Department of Pharmacy, Practice Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram

ABSTRACT

Chemotherapy is a pivotal modality in cancer management, characterized by complex pharmacotherapeutic regimens and a high capability for adverse drug events, necessitating multidisciplinary oversight to ensure optimal therapeutic outcomes. Pharmacists have emerged as integral members in optimizing chemotherapy through clinical interventions and operational management. Clinically, pharmacists engage in comprehensive chemotherapy protocol evaluation, individualized dose adjustments, management of treatment-related adverse drug reactions, patient counseling and the integration of pharmacogenomic data to personalize therapy. Operationally, pharmacists oversee the safe preparation, verification, and dispensing of cytotoxic agents, implement inventory control measures, and facilitate adherence to institutional guidelines and regulatory standards to mitigate medication errors. This review explores the evolving role of pharmacists in chemotherapy optimization, highlighting their impact on treatment efficacy, patient safety, and health care resource utilization. Despite, challenges such as limited recognition and resource constraints, the expanding scope of pharmacy practice presents opportunities for improved cancer care. The evolving role of pharmacists in cancer care supported by emerging technologies and collaborative care models, positions them as vital contributors in optimizing chemotherapy outcomes and advancing oncology care delivery.

Key words: Chemotherapy, Pharmacist Interventions, Oncology care

INTRODUCTION

Cancer remains a key driver of morbidity and mortality worldwide, with chemotherapy constituting a cornerstone to handle many malignancies [1]. Despite advances in therapeutic agents, complexity of chemotherapy regimens which often involve anti-cancer agents possessing restricted therapeutic spans, demands meticulous attention to dosing, scheduling and toxicity management for enhancing drug response yet limiting toxicity [2]. Ensuring the reliable and potent delivery of chemotherapy necessitates a multidisciplinary

approach, in which pharmacists have increasingly become indispensable members of the oncology care services [3].

Pharmacists have progressively assumed an essential role within oncology care teams, contributing both clinically and operationally to sound administration of chemotherapy [4]. From a clinical perspective, pharmacists conduct comprehensive chemotherapy protocol reviews, verification, and individualized management including dose adjustments for renal/hepatic function, drug interaction assessments, and limiting and addressing harms [3,5]. They also serve crucial function in educating patients and caregivers to promote compliance alongside well-being [6]. Furthermore, the integration of pharmacogenomic data into clinical decision-making has expanded the pharmacist's role in personalizing cancer therapy, facilitating targeted treatment approaches that improve outcomes [7].

On the operational front, pharmacists oversee the accurate preparation, verification and dispensing of chemotherapeutic agents, implementing stringent safety protocols to prevent medication errors and occupational exposure [8]. They manage inventory control and supply chain logistics to avoid drug shortages and ensures the availability of critical medications [4,9]. Additionally, pharmacists develop, implement, and audit institutional chemotherapy guidelines and standard operating procedures to ensure compliance with national and international regulations. Their active participation in multidisciplinary tumor boards and clinical research further enhances oncology care delivery [3,10].

These dual clinical and operational involvement positions pharmacists uniquely to improve chemotherapy outcomes by minimizing medication errors, enhancing treatment efficacy and reducing health care costs. Though such gains exist, notable barriers limit the total fulfillment of pharmacist's potential in chemotherapy management [3,8]. Variability in oncology pharmacy training, limited prescriptive authority, inadequate staffing and insufficient recognition within healthcare system pose barriers to expanding pharmacist-led interventions. Resolving these barriers through upgraded education, policy reform, and incorporation of digital health technologies is essential to strengthen the pharmacist's contribution to cancer care [3,6,8].

This review aiming to outline the entirety of the evolving role of pharmacists in optimizing chemotherapy from both clinical and operational perspectives. By synthesizing current evidence and best practices, this highlights pharmacist-driven interventions' impact on enhancing patient safety, treatment efficacy, and healthcare resource utilization. It further explores future directions for deeper pharmacist integration into multidisciplinary oncology services, ultimately improving chemotherapy treatment quality and outcomes.

PHARMACIST CONTRIBUTIONS IN ONCOLOGY THERAPEUTICS

Pharmacists play a multifaceted role in chemotherapy management, covering clinical and operational responsibilities that enhance safety, efficacy, and quality of cancer care. Their involvement ranges from direct patient care to operational oversight, ensuring appropriate and efficient use of chemotherapeutic agents across the treatment continuum.

a. Clinical Contributions of Pharmacists

Pharmacists contribute significantly at the patient interface by participating in direct clinical decision-making and monitoring. They also influence reliable deployment of chemotherapy regimens [11].

a. Chemotherapy Protocol Review and Validation.

Pharmacist carry major weight in the review and validation of chemotherapy protocols, making sure oncology regimens have both evidence-based and patient-specific. The protocol review and validation include:

- **Evidence-based assessment:** Pharmacists evaluate chemotherapy protocols for compliance with current established clinical guidelines such as National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) [12]. Pharmacists continuously stay updated with emerging clinical trial data and real-world evidence to confirm that the selected protocols reflect the most effective and safest treatment standards. They assess whether the chosen drug combinations, dosing sequences and treatment durations are supported by robust evidence for specific cancer types, stages and molecular subtypes [13]. Furthermore, pharmacists ensure that protocols incorporate any updates regarding newly approved agents, resistance patterns, biomarker-driven therapies or revised toxicity management recommendations [14,15].
- **Drug Selection and Dosing:** Pharmacist begins this process with evaluating whether the chosen chemotherapeutic agents are optimal for the specific cancer diagnosis, treatment intent like curative, adjuvant, neoadjuvant or palliative and patient profile. They ensure that the dosing is accurately calculated using patient-specific parameters, especially body surface area (BSA). Further tweaks occur depending on age, especially in geriatric oncology [16]. Performance status also assessed using standardized tools like the Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status (KPS) scales, provides a quantitative measure of patient's functional capacity and ability to tolerate intensive therapies. A poor performance status is often associated with reduced treatment tolerance, increased risk of adverse events and poorer survival outcomes [5,16,17]. In such cases, pharmacists collaborate with the oncology team to recommend dose modifications, supportive care intensification or even regimen de-escalation for treatment optimization [5, 18].
- **Supportive care integration:** Protocols are checked for inclusion of appropriate antiemetics, premedication, hydration protocols and growth factors when required thereby reduce treatment related complications [8, 19]. Incorporation of antiemetic therapy is one of the key elements in supportive care which is tailored to the emetogenic potential of the chemotherapeutic agents, in accordance with guidelines from organizations such as ASCO or MASCC [19, 20, 21]. Pharmacist also check for premedications such as corticosteroids, antihistamines or H2 antagonists, especially in protocols involving agents known to cause hypersensitivity reactions like taxanes or monoclonal antibodies [22, 23]. Hydration protocols are assessed to prevent renal toxicity in regimens containing nephrotoxic agents such as cisplatin or high dose methotrexate, ensuring that appropriate fluid volumes and diuretics are included [24]. Additionally, hematopoietic growth factors such as G-CSF or erythropoiesis-stimulating agents, are reviewed for inclusion in high-risk regimens to reduce the incidence of neutropenia, thrombocytopenia or anemia [25].

• **Drug interactions and Contraindications:** Pharmacists systematically screen for drug-drug interactions, particularly within oncology cases usually on multiple drugs targeting coexisting issues such as hypertension, diabetes, cardiovascular disease or infections. They also identify and address drug-food and drug-disease interactions [26, 27].

b. Dose Calculation and individualization.

Accurate dosing of chemotherapeutic agents is critical for amplifying treatment gains yet limiting toxicities. Dose individualization is commonly performed based on patient-specific parameters such as body surface area (BSA), renal and hepatic function and hematologic indices [10, 28]. BSA-based dosing remains the standard approach for many cytotoxic agents as it provides a rough estimate of metabolic capacity [29, 30]. However, renal and hepatic impairment necessitates further dose modifications, especially for drugs eliminated via these organs [31]. Pharmacist hold a key importance in assessing creatinine clearance or estimated glomerular filtration rate (GFR) to tailor dosing for those facing impaired renal capacity and in monitoring liver enzyme levels to adjust hepatically metabolized agents accordingly [32, 33]. Additionally, baseline and ongoing hematologic parameters such as absolute neutrophil count (ANC), hemoglobin and platelet levels, guide dose intensity and treatment scheduling, especially in myelosuppressive regimens [34].

c. Adverse Drug Reaction Monitoring and Management.

Adverse drug reactions are a significant concern in oncology due to the narrow therapeutic index of chemotherapeutic agents and the high potential toxicity. Pharmacists are uniquely positioned to identify, prevent and manage ADRs through systematic and ongoing monitoring throughout the treatment cycle [35]. This involves regular assessment of laboratory parameters (e.g., complete blood counts, liver and renal function tests), reviewing electronic medical records, evaluating patient-reported symptoms and analyzing drug regimens for potential interactions or cumulative toxicities [35, 36, 37]. Their close monitoring allows for the early detection of ADRs before they progress into severe or life-threatening complications [36].

In patients receiving cisplatin-based chemotherapy, pharmacists monitor for nephrotoxicity by assessing serum creatinine and electrolyte levels and may recommend and pre- and post-hydration protocols to prevent renal impairment [38,39]. Similarly, with 5-flurouracil, pharmacists observe for signs of mucositis and myelosuppression and may advocate for dose reduction or schedule adjustments if early toxicity signs emerge [40, 41].

In clinical practice, pharmacists intervene by recommending dose modifications, temporarily holding or permanently discounting offending agents and initiating supportive therapies such as antiemetics, growth factors, diuretics or hydration [42]. For example, in case of docetaxel-induced neutropenia [43], pharmacist may suggest prophylactic or therapeutic administration of granulocyte colony-stimulating factors (G-CSFs) like filgrastim to mitigate the risk of infection [44].

Pharmacists also play role in educating both patients and healthcare professionals. They counsel patients on the potential side effects of medications, the importance of adherence and the need to promptly report any new

or worsening symptoms. This patient centered education empowers individuals to recognize and respond to early signs of toxicity [45, 46]. For example, patients on PD-1 blockers like nivolumab are educated about immune-related adverse effects such as colitis or pneumonitis, enabling earlier reporting and management [37, 47].

Furthermore, pharmacists contribute significantly to institutional pharmacovigilance efforts. By documenting and reporting ADRs to local or national surveillance system, they help generate real-world safety records that shape future prescribing practices and update clinical guidelines [48].

In multidisciplinary oncology service, pharmacists serve as an essential link in communicating ADR trends and collaborating with oncologists, nurses, and other healthcare providers to tailor treatment plans according to patient specific factors such as age, comorbidities, organ dysfunction or pharmacogenetic considerations [49, 50]. For instance, among carriers of DPYD variants who are at high risk of severe 5-FU toxicity, pharmacists may recommend dose adjustments based on pharmacogenetic screening [51].

d. Patient Education and Adherence Counseling.

Pharmacist led patient counselling is a cornerstone in enhancing treatment adherence and ensuring reliable application of chemotherapeutic agents. This function gains special urgency amid oral chemotherapy, where patients self-administer complex regimens at home without the direct supervision of health providers. Non-adherence to oral anticancer agents can result in suboptimal treatment outcomes, disease progression and increased healthcare costs [52, 53].

Individualized counselling sessions provided by pharmacist covers:

- Mechanism of action and importance of adherence to the prescribed dosing schedule.
- Management of treatment drawbacks such as nausea, mucositis or fatigue which are typical triggers behind treatment discontinuation.
- Guidance on handling, storage and disposal of hazardous chemotherapeutic agents to prevent accidental exposure.
- Education on potential drug-drug and drug-food interactions, especially in patients on polypharmacy.
- Use of adherence aids such as pill organizers, mobile health apps or medication calendars.

Structured pharmacist counselling enhances adherence, minimizes errors, and boosts patient outcomes in cancer therapy, per studies from India and globally. A 2025 Indian iMAP trial in elderly patients improved MARS scores from 5.52 to 6.56 ($p<0.001$) versus standard care, alongside better quality of life [54].

Moreover, pharmacist also hold central importance for reinforcing adherence through follow-up calls or clinical visits, enabling initial spotting of barriers such as financial constraints, forgetfulness or psychological distress [55]. These interventions significantly lower the chances of treatment interruptions and boost treatment continuity.

Pharmacogenomics and personalized medicines.

Pharmacists are playing core involvement across integration of pharmacogenomic data into individualized therapy planning. For example, in oncology, pharmacogenomic testing is used to predict response to targeted therapies such as trastuzumab [56] (HER2 testing in breast cancer) or cetuximab [57] (KRAS/NRAS mutation status in colorectal cancer), allowing pharmacists to support precision medicine initiatives [7, 58].

Clinical pharmacists interpret pharmacogenomic test results and collaborate with oncologists or other prescribers to adjust chemotherapy regimens accordingly. They also provide education to patients and healthcare teams on the implications of specific genetic markers like CYP450 polymorphisms (e.g., CYP2D6, CYP2C19) that affects the metabolism of several chemotherapeutic agents [59]. Furthermore, pharmacists contribute to developing institutional guidelines and protocols for incorporating pharmacogenomic testing into routine care [60].

2. Operational Contributions of Pharmacists

Operational responsibilities ensure the safe handling, preparation and administration of cytotoxic drugs while maintaining system-level quality and regulatory compliance.

a. Chemotherapy Preparation and Verification.

Pharmacist carry strong influence in the aseptic preparation and verification of chemotherapy agents, ensuring both safety and accuracy. This process is typically conducted in certified sterile environments such as ISO Class 5 biological safety cabinets (BSCs) or laminar airflow workbenches situated with Class 7 controlled environments aligned with USP <797> and <800> guidelines. These standards are essential to prevent microbial contamination, cross-contamination and hazardous drug exposure thus protecting both patients and healthcare personnel [61]. Pharmacy professionals handle checking prescriptions against protocols and patient-specific parameters including body surface area, renal and hepatic function, neutrophil counts, platelet levels and drug interaction profiles [62]. This helps in avoiding overdosing or underdosing which can lead to toxicity or therapeutic failure. They also oversee sterile compounding which involves precise reconstitution, dilution and labeling of cytotoxic drugs via closed system drug transfer devices (CSTDs) where available. Double-checking of calculations, drug concentrations, infusion volumes and compatibility is a crucial step before final product release [61, 63].

Advanced technologies such as barcode scanning, gravimetric analysis and robotic compounding systems are increasingly utilized to enhance accuracy and reduce human error [64, 65]. In some centers, pharmacists also perform real time documentation and electronic verification within the oncology electronic health record (EHR) system [66]. Furthermore, pharmacists implement standard operating procedures (SOPs) for handling, storing and disposing of hazardous medications, thereby maintaining compliance with occupational safety set by organizations [67, 68].

b. Dispensing and Labeling in Chemotherapy.

Accurate dispensing and clear labeling are essential to ensure the safe administration of chemotherapeutic agents, which often have narrow therapeutic indices and complex dosing regimens [69]. Pharmacists stand central for verifying dispensed chemotherapy, matches the prescription and features complete, legible, clinically appropriate labelling. Key label components include patient name and identifiers, drug name and concentration, administration route and rate, diluent/volume (if applicable), preparation and expiry details, and handling precautions. These elements prevent administration errors in high-risk oncology settings. [70, 71].

c. Inventory and Supply Chain Management.

Pharmacists drive core efforts within managing the inventory and supply chain of chemotherapeutic agents to ensure continuous availability and prevent treatment delays. Their responsibilities include demand forecasting, procurement planning, expiration tracking and coordination with suppliers to address potential shortages [72]. Proactive inventory monitoring helps mitigate the risk of stockouts, which is particularly vital in oncology where treatment schedules are time-sensitive and interruptions can compromise therapeutic outcomes [73].

Pharmacists implement therapeutic substitution protocols during drug shortages, consulting oncology teams to select alternatives with comparable efficacy and safety. This approach maintains care quality while adhering to national procurement policies and pharmacoeconomic principles, optimizing resource use [74].

d. Development of Guidelines and SOPs.

Pharmacists ssupport primary advancement of standardized guidelines and Standard Operating Procedures (SOPs) for safe, consistent chemotherapy administration. Their expertise in pharmacokinetics, dosing, and safety enables collaboration with oncologists and nurses to create order sets with dose calculations, supportive care, and monitoring. These standardized templates help reduce prescribing variability and minimize errors during chemotherapy administration [76, 77].

SOPs include emergency spill response procedures and staff training requirements enhancing institutional readiness for accidental exposures [78]. Regular review and updating of these protocols based on emerging clinical evidence and updated national or international guidelines [79, 80], further ensure ongoing compliance and patient safety.

e. Quality Assurance and Risk Reduction.

Pharmacist play a crucial role in enhancing quality assurance and minimizing risks in oncology settings through systematic audits, medication use evaluations and root cause analysis of adverse events. Their active participation in multidisciplinary quality improvement initiatives helps identify gaps in chemotherapy safety and implement corrective actions [81].

INTERVENTIONS ACROSS CHEMOTHERAPY PHASES

Pharmacist play a vital role throughout the continuum of chemotherapy from initial treatment planning to post treatment follow-up. Their interventions across the different phases of chemotherapy enhance safety, optimize

therapeutic outcomes and support cost-effective care [10, 50]. These phases can broadly be classified into**: Pre-Chemotherapy (Planning), During Chemotherapy Administration and Monitoring) and Post-Chemotherapy (Follow-up and Long-term Management).**

a) Pre-Chemotherapy Phase.

Pharmacist contributions at this stage are crucial in optimizing treatment design and minimizing potential risks before chemotherapy is initiated.

- Regimen Review and Validation: Pharmacists review oncologist prescribed regimens for appropriateness based on tumor type, stage and guideline adherence [12].
- Dosing individualization: Accurate dose calculations based on body surface area, renal and hepatic function and performance status are critical. Pharmacists adjust doses for nephrotoxic agents like cisplatin, methotrexate, and carboplatin using creatinine clearance to mitigate toxicity risks [82].
- Pharmacogenetic Screening: In institutions with advanced pharmacogenomics services, pharmacists screen for genetic polymorphisms (e.g., DPYD, UGT1A1, TPMT) that predispose patients to severe toxicities from drugs like fluoropyrimidines, irinotecan and thiopurines [58, 83].
- Pre-chemotherapy Patient Counselling: Pharmacists educate patients on treatment expectations, potential side effects, drug-food interactions and adherence strategies thus reducing anxiety and improving adherence [52, 55].

b) During Chemotherapy Phase

This phase involves the actual preparation, dispensing, administration support and clinical monitoring of chemotherapy.

- Sterile Compounding and Verification: Pharmacist ensure chemotherapy agents are compounded under aseptic conditions following USP <800> and local safety standards. Centralized preparation by oncology pharmacists reduces compounding errors and ensures traceability [61, 62].
- Real-time Clinical Monitoring: Pharmacists monitor laboratory results (CBC, LFTs, renal function) and clinical status to identify toxicities early. Pharmacist driven monitoring programs have been associated with a 30-40% reduction in adverse events [50, 84].
- Interaction Screening: Close monitoring of polypharmacy and drug-drug interactions is essential especially for patients receiving supportive care agents. Pharmacists proactively manage interactions with agents like warfarin or anticonvulsants [50, 81].
- Supportive Care Optimization: Pharmacists adjust antiemetic regimens based on emetogenic potential of the chemotherapy reducing nausea-related hospital visits [19].

c) Post-Chemotherapy Phase

Pharmacist continue to contribute to patient care well after the chemotherapy infusion ends.

- Toxicity Management and Symptom Control: Pharmacists help manage delayed adverse effects like mucositis, peripheral neuropathy or bone marrow suppression [35, 81].
- Adherence Support for Oral Chemotherapy: Post-treatment counselling and refill verification help maintain adherence to oral agents such as capecitabine, imatinib or lenalidomide [55, 85].
- Patient Education on Late Effects: Pharmacists provide education on long-term risks (e.g., secondary malignancies, cardiotoxicity) and counsel on necessary lifestyle modifications such as cardio protection for anthracycline treated patients [86].
- Care Coordination and Transitions: In coordination with physicians and nurses, pharmacists contribute to survivorship plans and manage transitions to palliative or maintenance therapies where applicable [50, 55].

IMPACT OF PHARMACIST INTERVENTIONS

Pharmacist interventions in oncology settings, particularly during chemotherapy, have demonstrated significant value across several dimensions of healthcare delivery.

1) Safety and Error Reduction

Pharmacists play a pivotal role in minimizing medication errors throughout the chemotherapy process, where even minor miscalculations can result in serious harm.

- Error Prevention at Prescription and Compounding: Studies show pharmacist-led regimen reviews detect and prevent chemotherapy errors in 5-22% of cases, intercepting most before patient [5].
- Chemotherapy Verification Systems: Pharmacist-controlled order verification (e.g., CPOE system) reduces prescription errors by 30-81% compared to manual workflows [87].
- Real-Time Laboratory Monitoring: Pharmacist interventions for dose adjustments based on renal/hepatic function improve compliant dosing (21% to 34%) and prevent toxicities like cisplatin nephrotoxicity or methotrexate hepatotoxicity [88].

2) Clinical Outcomes

Pharmacist participation in oncology care has shown measurable improvements in patient health outcomes, especially in toxicity management, symptom control and adherence.

- Improved adherence and therapeutic Response: Pharmacist interventions in oral chemotherapy improve adherence, correlating with better progression-free survival [89].
- Enhanced Symptom Control: Pharmacist optimized supportive care has led to fewer emergency visits for uncontrolled reactions such as stomach upset, vomiting and diarrhea [90].

3) Economical Outcomes

Pharmacist led services offer a favorable economic profile through cost savings, improved resource utilization and prevention of adverse events.

- Cost Avoidance from Error Prevention: Clinical pharmacy services in oncology prevent adverse events, saving $100–$540 USD (~₹8,000–₹45,000 INR) per intervention and over $1M USD annually in large centres [91].
- Optimized Use of High-Cost Medications: Pharmacists minimize wastage via dose rounding, vial sharing, and discontinuing ineffective regimens, saving above $1M in targeted therapies [92].
- Reduced Rehospitalizations: Pharmacist-led follow-ups cut 30-day readmissions by 15-25% in oncology, driving indirect savings [93].

4) Patient-Reported Outcomes

Patient-centered care metrics such as satisfaction, quality of life (QoL) and confidence in managing therapy are positively influenced by pharmacist engagement.

- Improved Quality of Life Scores: Pharmacist-led symptom management and education improve FACT-G scores, especially physical well-being and treatment satisfaction [94].
- Increased Patient-Satisfaction: Surveys show 80-90% satisfaction with pharmacist chemotherapy counselling and follow-up [95].
- Empowerment and Understanding: Counselling boosts understanding of administration, side effects, and restrictions, enhancing self-efficacy and reducing anxiety [6].

BARRIERS TO PHARMACIST INTERVENTION

Despite growing evidence of clinical and economic benefits, pharmacist involvement in chemotherapy faces institutional, professional, regulatory, and infrastructural barriers across settings.

A. Workplace Limitations and Training Gaps

- Specialized Training Deficits: Many pharmacists lack formal training in chemotherapy pharmacology, dosing, and toxicity management. An ISOPP survey of 35 countries found only 40% offer all advanced oncology pharmacy services, with 26% having residencies and 40% board certifications [96].
- Limited Staffing Rates: High patient-to-pharmacist ratios hinder in-depth individualized care. In many centres, pharmacists are overburdened with dispensing duties, leaving limited time for clinical interventions [97].

B. Role Ambiguity and Interprofessional Dynamics

Pharmacist integration into oncology care teams is often hampered by unclear role definitions and interprofessional resistance.

- Lack of Recognition: In many healthcare systems, the clinical role of pharmacists remains under recognized, particularly in decision making related to chemotherapy regimens and supportive care [5].

▪ Interprofessional Barriers: Oncologist and nurse resistance to pharmacist led interventions may arise from perceived overlap in responsibilities or unfamiliarity with pharmacist's clinical competence [98].

C. Regulatory and Policy Constraints

Institutional and national regulations can restrict pharmacist's scope of practice, particularly in lower income and developing healthcare systems.

▪ Limited Perspective Authority: In many countries, pharmacists are not permitted to adjust doses or initiate therapy changes despite clinical justification, limiting their expertise impact [50, 99].
▪ Inadequate Policy Frameworks: National cancer control programs rarely include provisions for integrating clinical pharmacy services in oncology care pathways leading to inconsistent implementation [100].

D. Resource And Infrastructure Challenges

Effective pharmacist interventions depend on access toward instant analytics platforms, live clinical data and supportive technologies.

▪ Lack of Access to Electronic Health Records (EHRs): In facilities where pharmacists lack access to laboratory data or prescribing systems, their ability to intervene in real time is severely compromised [101].
▪ Underdeveloped Clinical Decisions Tools: In settings without software for dose calculation, toxicity grading, or pharmacokinetic monitoring, pharmacists may rely on manual processes that increase workload and error risk [102].

E. Financial and Institutional Support Deficits

Financial limitations and lack of institutional prioritization can prevent the establishment of clinical pharmacy services in oncology.

▪ Unfunded or unreimbursed Services: In many countries, clinical pharmacy tasks lack reimbursed, discouraging hospitals from allocating resources to pharmacist roles beyond dispensing.
▪ Cost Perception v/s Cost Effectiveness: Some administrators often view pharmacists as cost drivers rather than savings assets, despite evidence of economic benefits from adverse event prevention and therapy optimization. This stems from visible immediate costs like salaries and resource allocations, while economic benefits are less quantifiable and realized over time [103, 104].

F. Variability Across Healthcare Settings

▪ Urban-Rural Gaps: Oncology trained pharmacists are disproportionately located in tertiary or urban cancer centers, leaving peripheral hospitals without access to essential expertise.
▪ Inconsistent Implementation: Even within the same country, variability in hospital policies leads to unequal pharmacist participation in chemotherapy services [50, 99].

FUTURE DIRECTIONS

As cancer therapies advance with targeted agents, immunotherapies and personalized regimens, oncology pharmacists' roles will expand. Future efforts should optimize pharmacy service integration, scope, and recognition in cancer care.

- Expanding Pharmacist Roles in Precision Oncology.

With advancing pharmacogenomics and biomarker therapies, oncology pharmacists can interpret genomic data, guide personalised therapy selection and dosing based on molecular profiles, and contribute to tumour boards. This requires targeted precision medicine training programs [50].

- Integration of Digital Health and AI-Based Systems

Investments in digital infrastructure and pharmacist-friendly platforms are critical. Key technologies include AI-driven clinical decision support, mobile apps, electronic patient-reported outcomes (ePRO), telepharmacy, and digital monitoring tools [105].

- Standardization and Credentialing

Oncology pharmacy practice varies widely across institutions and countries. Future efforts should establish global and regional standards, credentialing pathways, and board certifications for consistent training and recognition, plus mandate pharmacist integration via accreditation bodies [86].

- Research and Outcome-Based Evaluation

Further high-quality studies are needed to solidify the evidence base for pharmacy interventions like large-scale randomized trials, Cost-effectiveness analyses and studies focusing on long-term outcomes [50].

- Policy, Advocacy and Funding.

Policy reforms should enable pharmacists to prescribe, adjust doses, and bill for cognitive services. Promote funding/grants for pharmacist-led oncology research. Professional bodies should push for pharmacists' inclusion in national cancer control strategies [86].

CONCLUSION

Pharmacists play a vital role across all chemotherapy stages, from regimen design and drug preparation to patient education, adverse effect management, and post-treatment monitoring. Their proactive clinical involvement enhances patient safety, optimizes therapeutic efficacy, reduces overall healthcare expenditure and improves cancer care quality. With the progressive shift toward complex and personalized chemotherapy protocols, the pharmacist’s responsibilities have expanded beyond conventional dispensing to advanced, patient-centered clinical functions.

Global evidence highlights the benefits of embedding pharmacists within multidisciplinary oncology teams. Models from developed nations such as the USA and the United Kingdom demonstrate the positive outcomes through advanced pharmacy practice, backed by specialized education, prescribing authority, and institutional recognition. However, in developing regions like India, significant potential remains to strengthen pharmacist participation through enhanced training, supportive policies, and organizational initiatives.

Despite the proven advantages, challenges including lack of uniform practice standards, insufficient clinical exposure, limited acknowledgment, and restrictive regulations continue to impede full integration of pharmacists into oncology services. Overcoming these barriers demands collaborative efforts among healthcare policymakers, academic institutions, and professional bodies to realize the full potential of pharmacy roles within tumor care.

REFERENCE

1. Egbewande OM, Abdulwasiu MA, Yusuf RO, Durojaye AB, Ashimiyu-Abdulsalam ZI. Roles of Community Pharmacists in Cancer Management. Innovations in Pharmacy. 2022;13(3):10.24926/iip.v13i3.4946.

2. Weingart SN, Zhang L, Sweeney M, Hassett M. Chemotherapy medication errors. Lancet Oncology. 2018;19(4):e191-9.

3. Runcie C.W. Who Reconstitutes the Chemotherapy? The Educational and Practice Needs of Oncology Pharmacists in West Africa: A Call for Multidisciplinary Team Approach in Oncology Care. JCO Global Oncology. 2025;11:e2500021.

4. Ma C. Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting. Integrated Pharmacy Research and Practice. 2014;3:11-24.

5. Knez L, Laaksonen R, Duggan C. Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiology and Oncology. 2010;44(4):249-56.

6. Poudel B, Sabkhi S, Pathak N, Basyal B, Poudel S, Nirmal Raj Marasine NR. Impact of pharmacist-led chemotherapy counseling on health-related quality of life and psychological outcomes of oncology patients in cancer hospital: A single center, open-label, randomized controlled trial. Exploratory Research in Clinical and Social Pharmacy. 2025;20:100649–9.

7. Filipski KK, Mechanic LE, Long R, Freedman AN. Pharmacogenomics in oncology care. Frontiers in Genetics. 2014;5:73.

8. Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A, Rothschild JM, Leape LL and Bates DW. Medication safety in the ambulatory chemotherapy setting†. Cancer. 2005;104:2477-83.

9. Coutsouvelis J, Siderov J, Tey AY, Bortz HD, O'Connor SR, Rowan GD, Vasileff HM, Page AT, Percival MA. The impact of pharmacist-led strategies implemented to reduce errors related to cancer therapies: a systematic review. Journal of Pharmacy Practice and Research. 2020;50:466-80.

10. Jetske D. Clinical Pharmacy Services in Oncology: Improving Chemotherapy Safety and Patient Outcomes. Journal of Basic and Clinical Pharmacy [Internet]. 2024 [cited Aug7];15(5):380. Available from:

https://www.jbclinpharm.org/articles/clinicalpharmacy-services-in-oncology-improving-chemotherapy-safety-and-patient-outcomes-13065.html

11. Mancini R. The Role of Oncology Pharmacists in the Care Team: Chemotherapy Management and Supportive Care at St. Luke's Mountain States Tumor Institute [Internet]. Oncology Practice Management. 2012 [cited 2025 Aug 7]. Available from: https://oncpracticemanagement.com/issues/2012/march-2012-vol-2-no-2/the-role-of-oncology-pharmacists-in-the-care-team-chemotherapy-management-and-supportive-care-at-st-luke-s-mountain-states-tumor-institute-march-2012

12. Zangardi ML. Evaluation of the Role of Clinical Pharmacists in the Review and Approval of Off-Label Oncology Treatment Requests [Internet]. The Journal of Hematology Oncology Pharmacy. 2018 [cited 2025 Aug 7];8(2). Available from: https://jhoponline.com/issue-archive/2018-issues/jhop-june-2018-vol-8-no-2/evaluation-of-the-role-of-clinical-pharmacists

13. Pearson D, Feng X, Listiawan M, Cheung C. Pharmacogenomic Biomarkers for Toxicities Associated with Chemotherapy [Internet]. US Pharmacist. 2012. Available from: https://www.uspharmacist.com/article/pharmacogenomic-biomarkers-for-toxicities-associated-with-chemotherapy

14. Alwardt S. Real-World Evidence Should Be Part of Clinical Trials in Oncology [Internet]. Onclive.com. OncLive. 2020 [cited 2026 Jan 13]. Available from: https://www.onclive.com/view/real-world-evidence-should-be-part-of-clinical-trials-in-oncology

15. Varnai P, Davé A, Farla K, Nooijen A, Petrosova L. The Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industry. Clinical Pharmacology & Therapeutics. 2020;110(5):1180–9.

16. Punke AP, Waddell JA. Creation and evaluation of a cancer chemotherapy order review guide for use at a community hospital. Journal of Oncology Pharmacy Practice. 2019;25(1):25-43.

17. Crandell BC, Bates JS, Grgic T. Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders. Journal of Oncology Pharmacy Practice. 2018;24(8):609-16.

18. S A. Optimizing chemotherapy dilution: A clinical pharmacist's perspective on safe and effective preparation - Kauvery Hospital [Internet]. Kauvery Hospital. 2025 [cited 2025 7 Aug]. Available from: https://www.kauveryhospital.com/kauverian-scientific-journal/chemotherapy-dilution-pharmacist-perspective/

19. Alamri A, Alawlah YA, Qiao Y, Wang J. A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting. SAGE Open Medicine. 2018;6:2050312118767234.

20. Herrstedt J, Clark-Snow R, Ruhlmann CH, Jordan K, Scotté F. MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update. Supportive Care in Cancer. 2023;32(1).

21. Idrees A, Kamal S, Baldwin S, Rong H, Nunez R, Flores MS, et al. Considerations for Chemotherapy-Induced Nausea and Vomiting in Adults [Internet]. US Pharmacist. 2025 [cited 2025 Aug 7];50(11):30-7. Available from: https://www.uspharmacist.com/article/considerations-for-chemotherapyinduced-nausea-and-vomiting-in-adults

22. Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunology and Immunotherapy. 2012;61(9):1575-84.

23. Premedication for prophylaxis of taxane hypersensitivity reactions [Internet]. Eviq.org.au. 2017 [cited 2025 Aug 7]. Available from: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/immunological/3264-premedication-for-prophylaxis-of-taxane-hyper

24. Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist. 2017;22(5):609-19.

25. Adamo V, Antonuzzo L, Danova M, De Laurentiis M, Marchetti P, Pinto C, Rosti G. Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: A Delphi consensus statement. Supportive Care in Cancer. 2022;30(12):9877-88.

26. Marcath LA, Xi J, Hoylman EK, Kidwell KM, Kraft SL, Hertz DL. Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics. Journal of Oncology Practice. 2018;14(6):e368–74.

27. DeRemer D. Clinically Relevant Drug Interactions in the Cancer Setting. Journal of the Advanced Practitioner in Oncology. 2022;13(3):231-5.

28. Siddiqui A, Shrestha S, Ahmed A, Akhlaq Bhutta O. Oncology stewardship: Role of the pharmacists for contribution in low and middle-income countries. Journal of Oncology Pharmacy Practice. 2023;29(4):956-7.

29. Body Surface Area for Adjustment of Drug Dose. Drug and Therapeutics Bulletin. 2010; 48(3):33–6.

30. Miller AA. Body Surface Area in Dosing Anticancer Agents: Scratch the Surface. Journal of the National Cancer Institute. 2002;94(24):1822–31.

31. Bouleftour W, Viard A, Mery B, Chaux R, Magne N, Simoens X, et al. Body surface area capping may not improve cytotoxic drugs tolerance. Scientific Reports. 2021;11(1).

32. McMahon BA, Rosner MH. GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer. Kidney360. 2020;1(2):141-50.

33. Eklund JW, Mulcahy MF. Chemotherapy Dosing in the Setting of Liver Dysfunction. Cancer Network [Internet]. 2005 [cited 2025 Aug 7];19(8). Available from: https://www.cancernetwork.com/view/chemotherapy-dosing-setting-liver-dysfunction

34. Jia H, Liang L, Chen X, Zha W, Diao W, Zhang W. Predictive value of peri-chemotherapy hematological parameters for febrile neutropenia in patients with cancer. Frontiers in Oncology. 2024;14:1380195.

35. Lavan AH, O'Mahony D, Buckley M, O'Mahony D, Gallagher P. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability. Oncologist. 2019;24(9):e968-77.

36. Bhatt S, Jhaveri R. The Role of a Pharmacist in Immunotherapy Related Adverse Effects [Internet]. ACCCBuzz Blog. 2026 [cited 2026 Aug 9]. Available from: https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/08/17/the-role-of-a-pharmacist-in-immunotherapy-related-adverse-effects

37. Medina P, Jeffers KD, Trinh VA, Harvey RD. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. Journal of Pharmacy Practice. 2020;33(3):338-49.

38. Almanric K, Marceau N, Cantin A, Bertin É. Risk Factors for Nephrotoxicity Associated with Cisplatin. Canadian Journal of Hospital Pharmacy. 2017;70(2):99-106.

39. Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Beladi Mousavi SS. Prevention of cisplatin nephrotoxicity. Journal of Nephropharmacology. 2015;5(1):57-60.

40. Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemotherapy and Pharmacology. 2016;78(3):447-64.

41. Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, et al. 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget [Internet]. 2018;9(14):11559–71.

42. Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists' modifications of prescription errors. British Journal of Clinical Pharmacology. 2004;58(5):503-11.

43. Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Management and Research. 2014;6:253-9.

44. Primary G-CSF prophylaxis following docetaxel treatment [Internet]. Njmonline.nl. 2019 [cited 2026 Aug 9].
Available from: https://njmonline.nl/article_ft.php?a=2156&d=1420&i=230

45. Poudel B, Sabkhi S, Pathak N, Basyal B, Poudel S, Marasine NR. Impact of pharmacist-led chemotherapy counseling on health-related quality of life and psychological outcomes of oncology patients in cancer hospital: A single center, open-label, randomized controlled trial. Exploratory Research in Clinical and Social Pharmacy. 2025;20:100649–9.

46. Wick JY. Chemotherapy: Managing Side Effects. Pharmacy Times [Internet]. 2014 [cited 2025 Aug 9];80(9). Available from: https://www.pharmacytimes.com/view/chemotherapy-managing-side-effects

47. Cheema PK, Iafolla MAJ, Nematollahi M, Berco F, Kaushik D, Matthews P, Raskin WR, Perdrizet KA, Dudani S, Husain J, Balcewicz M, Kuruvilla PG, Reingold SM, Conter HJ. A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre. Current Oncology. 2022;29(2):869-80.

48. Toklu HZ, Mensah E. Why do we need pharmacists in pharmacovigilance systems? Online Journal of Public Health Informatics. 2016;8(2):e193.

49. Guger-Halper U, Weber C, Alt M, Stangl M. EAHP — European Association of Hospital Pharmacists [Internet]. EAHP. 2024 [cited 2025 Aug 9]. Available from: https://eahp.eu/gpi_submission/pharmacist-multidisciplinary-oncology-team/

50. Holle LM, Segal EM, Jeffers KD. The Expanding Role of the Oncology Pharmacist. Pharmacy (Basel). 2020;8(3):130.

51. Granados J, Pasternak AL, Henry NL, Sahai V, Hertz DL. Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles. Clinical Pharmacology and Therapeutics. 2024;115(3):452-6.

52. Fisher CM, Kim AJ, Elder JJ. Impact of a Pharmacist-Led Chemotherapy Education Program on the Knowledge of Pediatric Hematology/Oncology Nurses. Journal of Pediatric Pharmacology and Therapeutics. 2017;22(5):332-7.

53. McKee M, Frei BL, Garcia A, Fike D, Soefje SA. Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. Journal of Oncology Pharmacy Practice. 2011;17(4):387–94.

54. Karoli S, M S Ganachari G. Impact of Pharmacist-Led Medication Optimization on Treatment Adherence and Quality of Life in Elderly Cancer Patients. Journal of Young Pharmacists [Internet]. 2025 [cited 2025 Nov 3];17(3):703–9.
Available from: http://dx.doi.org/10.5530/jyp.20251730

55. Bandiera C, Cardoso E, Locatelli I, Zaman K, Diciolla A, Digklia A, Stravodimou A, Cristina V, Aedo-Lopez V, Dolcan A, Sarivalasis A, Bouchaab H, Pasquier J, Dotta-Celio J, Peters S, Wagner D, Csajka C, Schneider MP. A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial. PLoS One. 2024;19(6):e0304573.

56. Kong X, Zhang K, Wang X, Yang X, Li Y, Zhai J, Xing Z, Qi Y, Gao R, Feng X, Wang J, Fang Y. Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas. Cancer Management and Research. 2019;11:5971-82.

57. Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Research Communications. 2023;3(10):2074-81.

58. Reizine N, Vokes EE, Liu P, Truong TM, Nanda R, Fleming GF, Catenacci DVT, Pearson AT, Parsad S, Danahey K, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Implementation of pharmacogenomic testing in oncology care (PhOCus): Study protocol of a pragmatic, randomized clinical trial. Therapeutic Advances in Medical Oncology. 2020;12:1758835920974118.

59. Işcan M, Ada AO. Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer. Turkish Journal of Pharmaceutical Sciences. 2017;14(3):319-23.

60. Haidar CE, Petry N, Oxencis C, Douglas JS, Hoffman JM. ASHP Statement on the Pharmacist's Role in Clinical Pharmacogenomics. American Journal of Health-System Pharmacy [Internet]. 2021 [cited 2025 Aug 9];79(8): 704-7. Available from: https://doi.org/10.1093/ajhp/zxab339

61. The Impact of USP 800 Guidelines on Compounding Chemotherapy Agents [Internet]. Wolterskluwer. 2020 [cited 2025 Sep 8]. Available from: https://www.wolterskluwer.com/en/expert-insights/the-impact-of-usp-800-guidelines-on-compounding-chemotherapy-agents

62. BC Cancer Clinical Pharmacy Guide [Internet]. [cited 2025 Sep 8]. Available from: https://www.bccancer.bc.ca/pharmacy-site/Documents/Clinical_Pharmacy_Guide/cpg2-checking-chemo-orders.pdf

63. <797> Pharmaceutical Compounding-Sterile Preparations [Internet]. USP. U S Pharmacopeia; [cited 2025 Sep 11].

Available from: http://ftp.uspbpep.com/v29240/usp29nf24s0_c797_viewall.html

64. Batson S, Mitchell SA, Lau D, Canobbio M, de Goede A, Singh I, Loesch U. Automated compounding technology and workflow solutions for the preparation of chemotherapy: A systematic review. European Journal of Hospital Pharmacy. 2020;27(6):330-6.

65. Geersing TH, Klous MG, Franssen EJF, van den Heuvel JJG, Crul M. Robotic compounding versus manual compounding of chemotherapy: Comparing dosing accuracy and precision [Internet]. European Journal of Pharmaceutical Sciences. 2020 [cited 2025 Sep 11];155:105536. Available from: https://doi.org/10.1016/j.ejps.2020.105536

66. Lukanawonakul A, Thanasitthichai S, Butthongkomvong K, Usa P, Sribundit N, Amnuay SL. Economic evaluation of a robotic chemotherapy compounding system and its service expansion to network hospital in Thailand. BMC Health Services Research. 2025;25(1002).

67. Hodson L, Ovesen J, Couch J, Hirst D, Lawson C, Lentz TJ, MacKenzie B, Mead K. Cincinnati, OH: U.S. Managing hazardous drug exposures: information for healthcare settings [Internet]. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2023-130 [cited on 2025 Sep 11].
Available from: https://doi.org/10.26616/NIOSHPUB2023130

68. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. American Journal of Health-System Pharmacists. 2018;75:1996-203.

69. Clinical Oncological Society of Australia. Guidelines for the Safe Prescribing, Dispensing and Administration of Cancer Chemotherapy [Internet]. 2008 [cited 2025 Sep 11]. Available from: https://www.cosa.org.au/media/1093/cosa_guidelines_safeprescribingchemo2008.pdf

70. Schulmeister L. What's New in the Updated Chemotherapy Administration Safety Standards? [Internet]. Oncnursingnews.com. Oncology Nursing News; 2017 [cited 2025 Sep 11];12(1). Available from: https://www.oncnursingnews.com/view/whats-new-in-the-updated-chemotherapy-administration-safety-standards

71. Trudeau M, Green E, Cosby R, Charbonneau F, Easty T, Ko Y, Marchand P, David U, Berger N, Hertz S. Key components of intravenous chemotherapy labeling: A systematic review and practice guideline. Journal of Oncology Pharmacy Practice. 2011;17(4):409-24.

72. Akter AK. Optimizing hospital pharmacy inventory management systems: Challenges and Solutions. Journal of Pharmacist and Hospital Pharmacy. 2024;1(1):07-10.

73. Martei YM, Grover S, Bilker WB, Monare B, Setlhako DI, Ralefala TB, Manshimba P, Gross R, Shulman LN, DeMichele A. Impact of Essential Medicine Stock Outs on Cancer Therapy Delivery in a Resource-Limited Setting. Journal of Global Oncology. 2019;5:1-11.

74. Shukar S, Shahid MH, Zhang J, Din SM, Khan FU, Fang Y, et al. Pharmacists' approach to oncology medicine shortages: results of a cross-sectional survey in Pakistan. BMJ Open. 2023;13(9):e070634-4.

75. Subratha C, Kumar N, Souza BD, Mavaji A, Kamath R. Inventory Management using Matrix Analysis and Inventory Index in an Oncology Pharmacy of a Tertiary Care Teaching Hospital. Journal of Young Pharmacists. 2018;10(1):78-81.

76. American Society of Clinical Oncology. ASCO/ONS Chemotherapy Administration Safety Standards. ONS [Internet]. www.ons.org. Available from: https://www.ons.org/ascoons-chemotherapy-administration-safety-standards

77. Krzyzanowska M, Oza A, Viswabandya A, Chudak A, Trypuc J, Gospodarowicz M. CHEMOTHERAPY [Internet]. University Health Network; 2018 [cited 2025 Sep 11]. Available from: https://cancerpedia.ca/chapters/Chemotherapy.pdf

78. Environmental Health & Safety. Chemotherapy and Other Hazardous Drugs Safe Use Guidelines [Internet]. University of Washington; 2015 [cited 2025 Sep 11]. Available from: https://www.ehs.washington.edu/system/files/resources/chemo-hazdrug-safety.pdf

79. American Society of Clinical Oncology. Guidelines, Tools, & Resources [Internet]. ASCO. [cited 2025 Sep 11]. Available from: https://www.asco.org/practice-patients/guidelines

80. ESMO. Oncology Clinical Practice Guidelines | ESMO [Internet]. Esmo.org. 2019 [cited 2025 Sep 11]. Available from: https://www.esmo.org/Guidelines

81. Ali T, Siddiqui A, Bhutta OA, Mazhar S, Usman A, Raza I, Pathak N, Shrestha S. Improving Clinical Pharmacist Performance in Oncology Care Through Education on Pharmaceutical Care Plans Documentation: A Pre-post Interventional Study. Inquiry. 2025;62:469580251335819.

82. Gurney H. How to calculate the dose of chemotherapy. British Journal of Cancer. 2002;86(8):1297-302.

83. Moen EL, Godley LA, Zhang W, Dolan ME. Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Medicine. 2012;4(11):90.

84. Seung AH, Palatine J, Merten J. Oncology Pharmacists Bring Value and Contribute to Cancer Care. Pharmacy times. [Internet]. 2023 [cited 2025 Dec 24];5(2). Available from: https://www.pharmacytimes.com/view/oncology-pharmacists-bring-value-and-contribute-to-cancer-care

85. Broadfield L, Shaheen P, Rogez M, Jamieson K, McCallum M. Guidelines for outpatient cancer care by community pharmacists. Canadian Pharmacist Journal. 2016;150(1):24-31.

86. Xiang HW, Shen YY, Wang JX, Zhao Y, Yi BW, Zhao N. Impact of pharmacist-led interventions on oncology drug therapy outcomes: A systematic review and meta-analysis. International Journal of Pharmacy Practice. 2026;34(2):117-29.

87. Stonerock DS, Clark K, Shah V, Irvine CC, Draper E, Soefje SA. Evaluating the Impact of Pharmacist Dual Verification of Anticancer Therapy in the Modern Era. Journal of Pharmacy Technology. 2023;39(6):281-5.

88. Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Scientia Pharmaceutica. 2017;85(1):8.

89. Zhao IC, Lai J, Seiki B, Wilson M, Brennan LA, Li T, Wun T. Evaluation of a pharmacist-driven oral chemotherapy adherence program. Journal of Clinical Oncology. 2015;33(15_suppl):6569–9.

90. Gershman J. Pharmacists Can Improve Adherence to Oral Oncolytics [Internet]. Pharmacytimes. 2022 [cited 2025 Dec 24]. Available from: https://www.pharmacytimes.com/view/pharmacists-can-improve-adherence-to-oral-oncolytics

91. Parsons LB. Positive Outcomes Associated with a Pharmacist-Driven Oral Chemotherapy Program [Internet]. The Journal of Hematology Oncology Pharmacy. 2025 [cited 2025 Dec 24]. Available from: https://jhoponline.com/issue-archive/2015-issues/2015-11-28-06-34-43/positive-outcomes-associated-with-a-pharmacist-driven-oral-chemotherapy-program

92. Kendzierski D. Pharmacist-Led Initiatives Drive Cost Reduction in Oncology Care [Internet]. Targetedonc.com. Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways; 2025 [cited 2025 Dec 24]. Available from: https://www.targetedonc.com/view/pharmacist-led-initiatives-drive-cost-reduction-in-oncology-care

93. Abdulwahid O. The Role of Clinical Pharmacists in Reducing Adverse Drug Reactions in Oncology Patients: A Multicenter study. Onkologia i Radioterapia [Internet]. 2025 [cited 2025 Dec 24];19(9). Available from: https://www.oncologyradiotherapy.com/articles/the-role-of-clinical-pharmacists-in-reducing-adverse-drug-reactions-in-oncology-patients-a-multicenter-study-1104218.html

94. McNabb L, Metrot E, Ferrington M, Sunderland B, Parsons R, Copeland TS, Corscadden S, Tong S, Czarniak P. Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic. PLoS One. 2024;19(6):e0304011.

95. Dennison T, Deal AM, Foster M, Valgus J, Muluneh B. A Pharmacist-Led Oral Chemotherapy Program's Impact on Chronic Myeloid Leukemia Patient Satisfaction, Adherence, and Outcomes. Journal of Advanced Practitioner in Oncology. 2021;12(2):148-57.

96. Ryan M, Zapata EH, Weru I, Cracknell ANV. Global oncology pharmacy service levels and knowledge requirements: A review by the International Society of Oncology Pharmacy Practitioners. Journal of Oncology Pharmacy Practice. 2025;31(7):1104-1114.

97. Shao SC, Chan YY, Lin SJ, Li CY, Kao Yang YH, Chen YH, Chen HY, Lai EC. Workload of pharmacists and the performance of pharmacy services. PLoS One. 2020;15(4):e0231482.

98. Moano GW, Adunlin G, Boyd K, Jumbo-Lucioni P, Bolaji B, Asare M. Perspectives of Pharmacists on the Structure, Decision-Making, and Communication Practices of Multidisciplinary Cancer Teams in Alabama. Journal of Pharmaceutical Innovation. 2022;13(1):10.24926/iip.v13i1.4298.

99. Sourisseau A, Fronteau C, Bonsergent M, Peyrilles E, Huon JF. Practicing and evaluating clinical pharmacy in oncology: Where are we now? A scoping review. Research in Social and Administrative Pharmacy. 2023;19(5):699–706.

100. Krauss ZJ, Abraham M, Coby J. Clinical Pharmacy Services Enhanced by Electronic Health Record (EHR) Access: An Innovation Narrative. Pharmacy (Basel). 2022;10(6):170.

101. Shulman LN, Miller RS, Ambinder EP, Yu PP, Cox JV. Principles of Safe Practice Using an Oncology EHR System for Chemotherapy Ordering, Preparation, and Administration. Journal of Oncology Pharmacy Practice. 2008;4(5):254-7.

102. Houle SK, Grindrod KA, Chatterley T, Tsuyuki RT. Paying pharmacists for patient care: A systematic review of remunerated pharmacy clinical care services. Canadian Pharmacists Journal. 2014;147(4):209-32.

103. Jermini M, Fonzo-Christe C, Blondon K, Milaire C, Stirnemann J, Bonnabry P, Guignard B. Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis. International Journal of Clinical Pharmacy. 2024;46(2):496-505.

104. Chander NK, A P, Chandra Ravi P, Muthiah A, Sharma Y, Suriyanarayanan G, P S S. Current trends on immunotherapy for oncology. Bioinformation. 2025;21(7):1880-5.

105. Liwarska J, Nowaczyk P, Brzykcy K, Szamałek M, Waszyk-Nowaczyk M. Oncology pharmacy education for pharmacy students - should it be improved? Reports of Practical Oncology and Radiotherapy. 2025;29(6):789-95.